• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

mohamed.fareh@unimelb.edu.au

Credentials


Position
Senior Research Fellow - Research Focussed
Centre for Cancer Research
ORCID

0000-0001-9551-8213

Mohamed Fareh

Senior Research Fellow - Research Focussed
Centre for Cancer Research

31 Scholarly works
14 Projects

HIGHLIGHTS

  • 2026

    Journal article

    De novo design of potent CRISPR–Cas13 inhibitors
    DOI: 10.1038/s41589-025-02136-3
  • 2026

    Journal article

    CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
    DOI: 10.1038/s41571-026-01179-2
  • 2025

    Journal article

    Systematic evaluation of CrRNA design parameters for optimized Cas13d-mediated RNA targeting in chicken cells
    DOI: 10.1007/s10142-025-01776-x
  • 2025

    Journal article

    Efficient mRNA delivery to resting T cells to reverse HIV latency
    DOI: 10.1038/s41467-025-60001-2
  • 2022

    Research grants (other domestic)

    Sequence-Specific Silencing of Oncogenic Drivers With Personalized Cas13 RNA Therapeutics
  • 2022

    Research grants (other domestic)

    mRNA-based Antiviral Therapeutics for SARS-CoV-2 Using Cas13
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    mRNA-based Antiviral Therapeutics for SARS-CoV-2 Using Cas13
Mohamed Fareh

RECENT SCHOLARLY WORKS

  • 2024

    Journal article

    Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision
    DOI: 10.1126/sciadv.adl0731
  • 2024

    Journal article

    Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing
    DOI: 10.1038/s41594-024-01336-0
  • 2024

    Journal article

    CRISPR-Cas13b-mediated suppression of HBV replication and protein expression
    DOI: 10.1016/j.jhep.2024.05.025
  • 2024

    Conference Proceedings

    CRISPR-Cas13b-mediated suppression of hepatitis B surface antigen-pre-clinical investigations of a new therapeutic approach
    DOI: 10.1016/s0168-8278(24)02081-6
  • 2024

    Journal article

    Utilizing CRISPR-Cas13 as a novel functional genomics tool to characterize PAX3-FOXO1 in alveolar rhabdomyosarcoma
    DOI: 10.1158/1538-7445.AM2024-1094
  • 2022

    Conference Proceedings

    De novo design of CRISPR-Cas13b enables efficient silencing of SARS-CoV-2 variants and tumour pathogenic RNAs with near single-base precision
    DOI: 10.1016/j.pathol.2021.12.057

RECENT PROJECTS

  • 2025

    Research grants (international)

    Direct and Indirect Targeting of HIV Tat for Selective RNA Degradation and Protein Suppression
  • 2025

    Research grants (other domestic)

    Developing CRISPR Cas13 Antiviral Therapeutics for Respiratory Pathogens of Pandemic Potential

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224